– I-Mab to its global presence in R
– The new one will complement I-Mab’s global clinical progression in Gaithersburg, Maryland, to shape an R Center
SHANGHAI and GAITHERSBURG, Md. , Oct. 22, 2021 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, progression and commercialization of new biologics, today announced the status quo of a new site targeting formula studies and translational medicine in San Diego. The incorporated laboratory and offices will strengthen the Company’s global progression capabilities, further strengthening I-Mab’s ability to conduct global clinical studies in China and the United States.
“Our vision for our new San Diego is to identify a world-class studio and operation as a component of the R Center.
“As a dynamic and developing U. S. biotechnology center, we are in the U. S. In the U. S. , San Diego is a wonderful selection because of its vast set of biopharmaceutical skills and its proximity to many of the world’s leading thinkies,” said Neil Warma, CEO of I-Mab US. we have been able to attract other world-class people in several key roles to our new San Diego site and are completing the final structure of the site, with a move planned for the end of the year. This is a very exciting time for I-Mab as we strategically expand our functions to carry out clinical progression globally to promote new treatments for patients,” added Warma.
Founded in 2016, I-Mab is committed to providing cutting-edge cancer remedies to patients around the world, building on the company’s clinical strengths in immuno-oncology and its strong portfolio of 20 cutting-edge active ingredients in progression. as a strategic site for I-Mab’s global drug progression efforts and will come with a comprehensive biomarker platform that will include existing and long-term clinical trials. The new study site will be an integral component of the R center
The company is preparing for immediate expansion over the next two years through significant investments in the U. S. USA For the progression of your state-of-the-art production line. oncology, translational medicine, chemistry, production and controls (CMC).
About I-Mab
I-Mab (Nasdaq: IMAB) is a dynamic global biotechnology company that exclusively aims at the discovery, progression and upcoming commercialization of novel or highly differentiated biologics in the healing spaces of immuno-oncology and autoimmune diseases. to patients around the world through innovation I-Mab’s cutting-edge portfolio of more than 10 clinical and preclinical drug applicants is guided through R’s Fast-to-PoC (Proof of Concept) and Fast-to-Market progression methods
For more information, please contact:
I-MabJielun Zhu, CFO Email: jielun. zhu@i-mabbiopharma. com Phone: 86 21 6057 8000
Gigi Feng, Director of Communications Email: gigi. feng@i-mabbiopharma. com Phone: 86 21 6057 5709
View Content: https://www. prnewswire. com/news-releases/i-mab-expands-us-footprint-with-new-rd-site-in-san-diego-301406493. html
SOURCE I-Mab